Axsome Therapeutics Inc (STU:19X)
€ 81.28 -1.42 (-1.74%) Market Cap: 3.94 Bil Enterprise Value: 3.83 Bil PE Ratio: 0 PB Ratio: 40.50 GF Score: 36/100

Axsome Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2022 / 03:40PM GMT
Release Date Price: €59.74 (-1.29%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst

Thanks, everyone, for joining. This is a fireside chat with Axsome Therapeutics. Let me read a brief disclosure statement before we get started. So for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. My name is Vikram Purohit. I'm one of the biotech analysts with the research team. Happy to have with me Herriot Tabuteau, CEO; and Mark Jacobson, COO of Axsome. Thanks for joining us.

Herriot Tabuteau
Axsome Therapeutics, Inc. - Founder, Chairman, CEO & President

Thank you.

Questions & Answers

Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst

So before we get into any specifics around pipeline Auvelity et cetera. Herriot, do you want to just level set for the audience and just provide a recap of some of the key milestones Axsome through work to do

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot